HCC

OTX-2002 has received an orphan drug designation by the FDA for patients with hepatocellular carcinoma. The agent will further be evaluated in the phase 1/2 MYCHELANGELO trial.

Pierre Gholam, MD, discusses standard of care options for hepatocellular carcinoma, including newly-available therapies.

Considering the higher-than-average rate of liver cancer in Texas as a whole, it was unexpected that the Kashmere Gardens neighborhood cluster would be linked to environmental issues. Texas Department of State Health Services and the City of Houston confirm the cluster exists and is caused by toxins polluted into the soil by The Union Pacific Railroad.

Richard S. Finn, MD, discusses the background on lenvatinib and what led to the development of the LEAP-002 trial.

During a live virtual event, Ghassan K. Abou-Alfa, MD, discussed the results of the REFLECT trial of lenvatinib versus sorafenib and the LEAP-002 trial of lenvatinib/pembrolizumab versus lenvatinib in patients with hepatocellular carcinoma.

Mahvish Muzaffar, MD, and Nasreen Vohra, MD, from the Brody School of Medicine/East Carolina University, discuss the past decade of progress in treatment for patients with hepatocellular carcinoma.

Findings from the phase 3 HIMALAYA trial have led the FDA to grant approval to the combination of tremelimumab and durvalumab for the treatment of patients with unresectable hepatocellular carcinoma.

TTI-101, an oral, small molecule, STAT3 inhibitor, has been granted fast track designation by the FDA for patients with hepatocellular carcinoma.

Data presented during the 2022 International Liver Cancer Association Conference showed that less than one-third of patients with hepatocellular carcinoma who received regorafenib followed by nivolumab experienced grade 3 or 4 treatment-related adverse events.

The phase 1b Study 116/KEYNOTE-524 trial of lenvatinib and pembrolizumab revealed the RAS gene signature to possibly be associated with progression-free survival in unresectable hepatocellular carcinoma.

In an interview with Targeted Oncology, Ghassan K. Abou-Alfa, MD, discussed 3 late breaking abstracts in the hepatocellular carcinoma space currently influencing the field.

Richard S. Finn, MD, led a discussion on the management of patients with advanced hepatocellular carcinoma.

In an interview with Targeted Oncology Richard Finn, MD, discussed the implications of the LEAP-002 trial.

In an interview with Targeted Oncology, Pierre Gholam, MD, discussed multiple studies currently influencing the hepatocellular carcinoma treatment landscape.

At the 2022 ESMO Congress, results from the final analysis of the RATIONALE-301 study showed that tislelizumab monotherapy continued to have clinically meaningful anti-tumor activity vs sorafenib in patients with unresectable hepatocellular carcinoma.

Although the combination use of lenvatinib plus pembrolizumab did not induce statistically significant differences in the co-primary end points, the LEAP-002 trial induced the longest seen median overall survival with lenvatinib monotherapy in patients with unresectable HCC.

Findings presented at ESMO 2022 show the survival benefits of camrelizumab plus rivoceranib in patients with unresectable HCC.

Mark Yarchoan, MD, discusses the current hepatocellular carcinoma space as well as 3 late breaking abstracts that will be presented at the 2022 ESMO Congress.

Daneng Li, MD, discusses potential second-line options following treatment with bevacizumab plus atezolizumab in patients with hepatocellular carcinoma.

During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, MBA, discussed the case of a patient with hepatocellular carcinoma whose comorbidities impacted the choice of treatment.

The phase 3 RATIONALE 301 trial of tislelizumab in patients with unresectable hepatocellular carcinoma has met its primary end point of non-inferior overall survival.

Arndt Vogel, MD, discusses the study results of the IMMUTACE study in hepatocellular carcinoma.

While treatment with pembrolizumab and lenvatinib vs lenvatinib alone seemed to have survival benefit in patients with unresectable hepatocellular carcinoma, the primary end points of the trial were missed.

Ghassan K. Abou-Alfa, MD,discusses the phase 2 study of tislelizumab in patients with unresectable hepatocellular carcinoma.

According to Lorenza Di Marco, PhD, immunotherapy treatment can increase the risk of liver rejection in patients with recurrent HCC who have undergone a liver transplant.